Camp4 Therapeutics Corp (CAMP) stock
CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3063% above fair value
$4.09−0.11 (-2.62%)
Close on Nov 12, 2026Market cap $256.66MP/E –Yield 0.00%
Camp4 Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Camp4 Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$51.36M. For fiscal 2025 it was -$50.92M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$50.92M | – |
| FY2024 | Dec 31, 2024 | -$51.39M | – |
| FY2023 | Dec 31, 2023 | -$50.20M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$13.53M | – |
| Q2 FY2026 | Jun 30, 2026 | -$12.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.55M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.25M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.63M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.62M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.44M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.04M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.94M | – |
See a number that looks wrong?